Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 30, 2022
Daily News
September 30, 2022
- Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
- Crecon President Sounds Alarm over Hollowing-Out of Domestic Manufacturing
September 30, 2022
- Trade Group Calls for New Pricing Model for Regenerative Medicine Products
September 30, 2022
- Ferring Japan CEO Confident of Growth in Fertility Drugs Spurred by Rising Demand on Health Coverage
September 30, 2022
- Lilly Japan, DeNA Partner Up to Recruit Trial Participants with Collected Genetic Data
September 30, 2022
- US QIDP Status Awarded to Meropenem Combo Med for Carbapenem-Resistant Bacteria Infections: Kitasato/Sumitomo
September 30, 2022
- Japan Set to Distribute Pfizer’s COVID Jab for 6 Months to 4 Years of Age from Late October
September 30, 2022
- Chugai Files Perjeta/Herceptin Subcutaneous Combo in Japan
September 30, 2022
- 2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…